GlassScriptPhysician profile
Sean T Keesee
NPI 1003907098
$687.00
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $110 · 2021: $87.81 · 2022: $341.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $207.34 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $136.57 | 2019-2022 | |
| Boston Scientific Corporation | $104.58 | 2019 | |
| Abiomed | $49.71 | 2020 | |
| Pfizer INC. | $42.47 | 2021 | |
| Abbvie INC. | $36.84 | 2022 | |
| Merck Sharp & Dohme LLC | $35.52 | 2019-2020 | |
| Allergan, INC. | $28.82 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.12 | 2022 | |
| Cook Medical LLC | $13.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Keesee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.